Hypoparathyroidism Explained: Low PTH, Hypocalcemia, Hyperphosphatemia and Treatment

What Is Hypoparathyroidism?

Introduction

Hypoparathyroidism is a disorder in which insufficient biologically effective parathyroid hormone activity leads to impaired calcium homeostasis.

The classic biochemical pattern is:

with:

and commonly:

The key word is:

because in hypocalcemia the normal physiological response is a substantial increase in PTH secretion.

Therefore a PTH result that lies inside the laboratory reference range can still be abnormal when serum calcium is low.

The 2025 ESE guideline recommends considering chronic hypoparathyroidism in patients with persistent hypocalcemia and PTH that is low or inappropriately normal. (OUP Academic)

Hypoparathyroidism at a glance

Calcium

PTH

Phosphate

Calcitriol

Urinary calcium

Can be:

especially during conventional treatment.

Major long-term problem

How PTH Controls Calcium, Phosphate and Calcitriol

Normal PTH physiology

Normally:

CaSR activation ↓

PTH then acts to restore extracellular calcium through:

Kidney

Kidney

Kidney

Intestine

indirectly:

Bone

PTH-dependent calcium mobilization can increase.

What happens when PTH is absent?

When PTH is deficient:

Kidney

Kidney

Kidney

Intestine

Therefore:

Core pathway

Kidney

Ca reabsorption ↓

PO₄ excretion ↓

calcitriol production ↓

Blood

Neuromuscular system

symptoms of hypocalcemia.

Why phosphate rises

PTH normally promotes:

Without PTH:

This is one of the most useful biochemical clues.

Memory rule:

while:

in many calcium disorders.

Why calcitriol falls

PTH stimulates renal:

Without sufficient PTH:

Therefore:

This is why chronic hypoparathyroidism is usually treated with:

rather than relying only on ordinary vitamin D.

Can PTH Be Normal in Hypoparathyroidism?

Suppose:

and:

A common error is:

“PTH is normal, therefore the parathyroids are functioning.”

Wrong.

The physiological question is:

Answer:

Therefore:

may represent:

and is compatible with hypoparathyroidism. (OUP Academic)

Typical Laboratory Pattern and Diagnosis

Diagnostic pattern

Confirm true hypocalcemia

Do not diagnose from one low total calcium result.

Assess:

• albumin-adjusted calcium;
• ionized calcium where needed;
• albumin;
• magnesium;
• renal function;
• acid-base context where relevant.

Endotext notes that ionized calcium can confirm true hypocalcemia when total calcium interpretation is uncertain. (NCBI)

First diagnostic branch

Once true hypocalcemia is established:

Then:

PTH elevated

The parathyroids are responding.

Think:

PTH low / inappropriate normal

Think:

Complete hypocalcemia–PTH algorithm

PTH ↑

Think:

• vitamin D deficiency;
• CKD;
• malabsorption;
• hypocalcemia from phosphate excess;
• pseudohypoparathyroidism;
• other secondary causes.

PTH ↓ / inappropriate normal

Severe hypomagnesemia?

Magnesium acceptable

Review:

Postsurgical Hypoparathyroidism and the 12-Month Definition

Most common cause in adults

The most common cause of acquired hypoparathyroidism is:

including:

• thyroid surgery;
• parathyroid surgery;
• extensive neck surgery.

Endotext identifies surgical removal or injury of the parathyroid glands as the most common cause of primary hypoparathyroidism with hypocalcemia and hyperphosphatemia. (NCBI)

Postsurgical hypoparathyroidism

Mechanisms include:

• accidental gland removal;
• vascular compromise;
• direct injury;
• devascularization;
• postoperative edema;
• transient suppression/dysfunction.

Hypoparathyroidism after neck surgery can be:

or:

Updated definition of chronic postsurgical hypoparathyroidism

This is an important current guideline update.

The 2025 revised ESE guideline defines postsurgical chronic hypoparathyroidism as:

because recovery can occur later than previously appreciated. (OUP Academic)

The older six-month cutoff should not be used as the default definition of chronic postsurgical disease.

Why recovery can occur late

Residual parathyroid tissue may gradually recover.

Therefore:

The guideline even recommends periodic assessment of endogenous PTH function in chronic postsurgical disease because recovery can occasionally occur later. (OUP Academic)

Autoimmune, Genetic and Other Causes

Nonsurgical causes

Important categories include:

• autoimmune hypoparathyroidism;
• genetic hypoparathyroidism;
• syndromic disease;
• infiltrative/destructive disease;
• severe magnesium disturbance;
• rare radiation or iron/copper-related gland injury.

Autoimmune hypoparathyroidism

Autoimmune destruction of parathyroid tissue can occur:

• in isolation;
• as part of autoimmune polyglandular syndromes.

Clinical clues include:

• other autoimmune endocrine disease;
• candidiasis in APECED contexts;
• adrenal insufficiency;
• other autoimmune features.

Genetic hypoparathyroidism

Possible mechanisms include genes involving:

• PTH production;
• parathyroid development;
• calcium sensing;
• transcriptional regulation;
• syndromic chromosomal disorders.

Examples may include:

• activating CASR variants;
• GCM2;
• GNA11;
• 22q11.2 deletion;
• selected syndromic causes.

The 2025 ESE guideline recommends considering:

in nonsurgical hypoparathyroidism without an obvious alternative cause. (OUP Academic)

Activating CaSR variants

This provides a useful contrast with FHH.

FHH

→ Ca ↑.

Activating CaSR disorders

PTH secretion suppressed at lower calcium

renal calcium wasting can increase.

Magnesium and Functional Hypoparathyroidism

Magnesium: critical diagnostic step

Magnesium is essential for:

• PTH secretion;
• PTH action.

Therefore severe:

can produce:

Endotext lists magnesium depletion as a cause of functional hypoparathyroidism. (NCBI)

How low magnesium causes hypocalcemia

Severe magnesium deficiency can cause:

and:

Therefore:

until magnesium is corrected.

Memory rule:

Magnesium excess

Severe hypermagnesemia can also suppress PTH secretion and contribute to hypocalcemia.

This is less common.

Hypoparathyroidism vs PTH Resistance, Vitamin D Deficiency and CKD

Pseudohypoparathyroidism

Pseudohypoparathyroidism is:

not PTH deficiency.

Typical biochemical pattern:

but:

This differentiates it from classical hypoparathyroidism.

Hypoparathyroidism vs pseudohypoparathyroidism

Memory rule:

Vitamin D deficiency differential

Vitamin D deficiency also causes hypocalcemic physiology.

But typical response is:

because the parathyroid glands are functioning.

Therefore:

Vitamin D deficiency

Ca ↓/normal

PTH ↑

PO₄ often ↓ because PTH wastes phosphate

versus:

Hypoparathyroidism

Ca ↓

PTH ↓

PO₄ ↑

CKD differential

CKD may cause:

• calcitriol deficiency;
• phosphate retention;
• hypocalcemia;
• secondary hyperparathyroidism.

Thus:

rather than low.

If a CKD patient has:

consider:

• hypoparathyroidism;
• oversuppressed PTH;
• adynamic bone/mineral context;
• magnesium or medication issues.

Symptoms and Chronic Manifestations

Clinical symptoms of hypocalcemia

Symptoms depend on:

• degree of hypocalcemia;
• rate of fall;
• chronicity.

Possible manifestations include:

• perioral tingling;
• distal paresthesia;
• muscle cramps;
• carpopedal spasm;
• tetany;
• weakness;
• seizures;
• laryngospasm;
• bronchospasm;
• neuropsychiatric symptoms;
• QT prolongation.

The 2025 ESE guideline notes severe manifestations can include seizures, cardiac failure, bronchospasm and laryngospasm. (OUP Academic)

Chvostek and trousseau signs

Chvostek sign

Facial muscle contraction after tapping the facial nerve.

Trousseau sign

Carpal spasm induced by prolonged blood-pressure cuff inflation.

Neither sign is perfectly sensitive or specific.

Chronic manifestations

Longstanding hypoparathyroidism can be associated with:

• basal ganglia or intracranial calcification;
• cataracts;
• renal stones/nephrocalcinosis;
• reduced renal function;
• neurocognitive symptoms;
• impaired quality of life;
• abnormal bone remodeling.

These complications do not occur in every patient.

Why Kidney Complications Occur

Why renal complications occur

PTH normally:

In hypoparathyroidism this effect is lost.

Conventional treatment raises serum calcium using:

but does not fully restore PTH-mediated renal calcium conservation.

Therefore:

while:

This creates risk of:

• nephrolithiasis;
• nephrocalcinosis;
• renal dysfunction.

The fundamental treatment problem

Why?

Because pushing serum calcium too high with conventional therapy can increase:

and:

The 2025 ESE guideline recommends aiming for serum calcium in the:

while controlling symptoms and minimizing complications. (OUP Academic)

Chronic Treatment Goals and Who Should Receive Treatment

Treatment goals

According to the 2025 ESE guideline, management aims to:

• reduce hypocalcemic symptoms;
• improve quality of life;
• maintain calcium in low-normal/slightly below range;
• avoid hypercalcemia;
• keep phosphate controlled;
• normalize magnesium;
• maintain adequate vitamin D;
• avoid hypercalciuria;
• preserve renal function. (OUP Academic)

Who should receive treatment?

The 2025 ESE guideline recommends treating:

• patients with hypocalcemic symptoms;

and/or:

• adjusted calcium below 8.0 mg/dL (2.0 mmol/L), corresponding approximately to ionized calcium below 1.00 mmol/L.

It also suggests offering treatment to apparently asymptomatic patients between this threshold and the lower limit of normal to assess whether wellbeing improves. (OUP Academic)

These are guideline-based thresholds for chronic treatment, not an emergency dosing protocol.

Conventional chronic treatment

The conventional treatment framework is:

with:

plus:

and management of:

Active Vitamin D: Calcitriol and Alfacalcidol

Why active vitamin D is used

In hypoparathyroidism:

Therefore endogenous calcitriol production is impaired.

So treatment commonly uses:

or:

where available.

The 2025 ESE guideline recommends an activated vitamin D analogue when available. (OUP Academic)

Calcitriol

Calcitriol is:

the active vitamin D hormone.

It increases:

and helps maintain serum calcium.

Alfacalcidol

Alfacalcidol is:

It is converted in the liver to active vitamin D.

It does not require renal 1α-hydroxylation.

Availability varies by country.

Ordinary vitamin D still matters

Even if active vitamin D is used, patients should maintain adequate:

The revised ESE guideline suggests:

as an adequate target. (OUP Academic)

This prevents concurrent nutritional vitamin D deficiency.

Calcium Intake, Supplements and Levothyroxine

Calcium intake

The revised ESE guideline suggests adult dietary elemental calcium intake around:

for nonpregnant adults.

Supplements may be added if target calcium cannot be achieved with:

• active vitamin D;
• adequate dietary calcium.

If calcium supplementation exceeds about:

the guideline suggests dividing it into smaller doses across the day. (OUP Academic)

Calcium carbonate vs calcium citrate

Calcium carbonate:

• requires gastric acid for optimal absorption;
• provides more elemental calcium per tablet.

Calcium citrate:

• is absorbed better in reduced gastric acidity;
• may be preferable after some bariatric procedures;
• may be useful with proton-pump inhibitor use/achlorhydria.

The revised guideline specifically notes calcium citrate may be preferable in patients after bariatric surgery because achlorhydria and malabsorption are common. (OUP Academic)

Important drug interaction

Calcium supplements can interfere with absorption of:

This matters because postsurgical hypothyroidism and hypoparathyroidism may coexist after thyroid surgery.

Do not take calcium supplements simultaneously with thyroid hormone replacement.

The ESE guideline specifically highlights this interaction. (OUP Academic)

Magnesium and Phosphate Management

Magnesium replacement

If magnesium is low:

The 2025 ESE guideline recommends measures to restore magnesium into the reference range. (OUP Academic)

This may be essential for:

• PTH secretion;
• PTH responsiveness;
• correction of hypocalcemia.

Phosphate management

The guideline recommends aiming for:

because hyperphosphatemia can contribute to:

• calcium-phosphate precipitation;
• ectopic calcification concerns;
• treatment burden.

Management may include:

• dietary measures;
• adjustment of calcium treatment;
• adjustment of active vitamin D.

If persistent despite optimized conventional therapy, PTH replacement may be considered. (OUP Academic)

Calcium × phosphate concept

The main teaching concept is:

Therefore avoid simultaneously overtreating calcium while phosphate remains high.

Hypercalciuria, Thiazides and Sodium Intake

Hypercalciuria

Conventional therapy can cause:

The 2025 ESE guideline uses hypercalciuria values:

Men

Women

or:

for either sex. (OUP Academic)

Why urinary calcium matters

A patient may have:

but:

Therefore serum calcium alone does not tell you whether treatment is safe.

Memory rule:

Management of hypercalciuria

The revised ESE guideline suggests:

• reducing unnecessary calcium supplement burden;
• adjusting active vitamin D;
• reducing sodium intake;
• considering a thiazide;
• considering PTH replacement if hypercalciuria persists despite optimized conventional therapy. (OUP Academic)

Why thiazides help here

Thiazides:

This can be useful in chronic hypoparathyroidism with problematic hypercalciuria.

This differs from their role in hypercalcemia diagnosis.

Sodium intake

High sodium intake increases urinary calcium excretion.

The 2025 ESE guideline suggests sodium restriction to:

equivalent to approximately:

when managing hypercalciuria. (OUP Academic)

Acute Symptomatic Hypocalcemia

Acute symptomatic hypocalcemia

Acute calcium principle

followed by:

as needed.

IV calcium is acute rescue treatment; ongoing chronic therapy follows the principles below.

Why calcium gluconate is commonly preferred

Compared with calcium chloride:

Calcium chloride contains more elemental calcium but is more irritating and is generally reserved for selected monitored/central-access contexts.

Acute treatment must also correct magnesium

If severe hypomagnesemia is present:

Therefore acute evaluation should include magnesium.

ECG

Hypocalcemia can prolong:

Severe symptomatic cases may require ECG monitoring during IV calcium treatment.

PTH Replacement Therapy and Palopegteriparatide

PTH replacement therapy

The 2025 ESE guideline recommends:

for chronic hypoparathyroidism when patients continue to have:

despite optimized conventional treatment with:

• active vitamin D;
• adequate calcium intake. (OUP Academic)

When to consider PTH replacement

The revised guideline suggests considering PTH replacement when one or more persist despite optimized conventional therapy:

• frequent calcium fluctuations;
• symptomatic hypocalcemia;
• impaired quality of life attributable to disease;
• eGFR <60 mL/min/1.73 m²;
• hypercalciuria;
• hyperphosphatemia. (OUP Academic)

This is a major update compared with older practice.

Why PTH replacement is physiologically attractive

Conventional treatment replaces:

and:

but does not replace the hormone responsible for:

• renal calcium conservation;
• phosphate excretion;
• calcitriol regulation.

PTH replacement restores more of the missing physiology.

Therefore it can:

and improve biochemical stability.

Current PTH replacement landscape

The 2025 ESE guideline notes that older rhPTH(1-84) products were withdrawn from the market by the end of 2024.

It identifies:

as an approved sustained PTH replacement option in jurisdictions including the EU and US at guideline publication. (OUP Academic)

Availability and reimbursement vary by jurisdiction and can change.

Palopegteriparatide

It is a long-acting prodrug that provides sustained release of:

The goal is more physiological PTH exposure across the day.

Clinical trial data have shown improvements in:

• serum calcium stability;
• urinary calcium;
• phosphate;
• supplement burden;
• some quality-of-life measures.

Long-term hard-outcome data remain limited. (OUP Academic)

Goal of PTH replacement

The revised ESE guideline suggests titrating PTH replacement toward:

while reducing or eliminating:

and:

when possible. (OUP Academic)

PTH replacement is not for every patient

A patient who is:

• asymptomatic;
• biochemically stable;
• with acceptable urinary calcium;
• preserved renal function;
• good quality of life;

may continue to do well with conventional treatment.

not automatic first-line replacement for everyone.

Long-Term Monitoring, Bone Health and Quality of Life

Monitoring

The 2025 ESE guideline recommends regular monitoring of:

• adjusted or ionized calcium;
• phosphate;
• magnesium;
• creatinine/eGFR;
• symptoms.

A typical suggested biochemical interval in stable chronic disease is:

with individualized adjustment. (OUP Academic)

PTH monitoring

The revised guideline suggests:

as appropriate,

particularly to assess for potential endogenous recovery in postsurgical disease. (OUP Academic)

24-hour urinary calcium

Urinary calcium should be assessed periodically and particularly when:

• treatment changes;
• stones/nephrocalcinosis suspected;
• renal function worsens;
• high supplement burden exists.

Renal monitoring

Assess:

• creatinine/eGFR;
• urinary calcium;
• history of nephrolithiasis;
• nephrocalcinosis;
• imaging when clinically indicated.

Long-term kidney complications are among the most important treatment-related concerns in chronic hypoparathyroidism.

Why bone density can be high

Chronic PTH deficiency reduces:

Therefore BMD may be:

This does not necessarily mean bone quality is completely normal or that skeletal monitoring is irrelevant.

Do not equate high BMD with “excellent bone health.”

Quality of life

Patients with chronic hypoparathyroidism may have persistent:

• fatigue;
• cognitive symptoms;
• mood symptoms;
• neuromuscular symptoms;
• treatment burden;

even when calcium appears “acceptable.”

The 2025 ESE guideline explicitly includes:

as a major management goal and as one potential indication for considering PTH replacement when impaired despite optimized treatment. (OUP Academic)

Complete Diagnostic Algorithm

Interpret persistent biochemical findings with the clinical context. Urgent symptomatic hypocalcemia requires stabilization alongside investigation.

Complete Chronic Treatment Algorithm

1. Assess symptoms, calcium, phosphate, magnesium and renal function.
2. Use active vitamin D and adequate dietary calcium; add calcium supplements if required.
3. During conventional treatment, target symptom control and low-normal or slightly low calcium; avoid overtreatment.
4. Monitor urinary calcium, phosphate, magnesium and eGFR.
5. Hypercalciuria: adjust calcium/active vitamin D, reduce sodium and consider a thiazide. Consider PTH replacement if the problem persists despite optimized treatment.
6. Hyperphosphatemia: adjust diet and calcium/active vitamin D. Consider PTH replacement if persistent despite optimized treatment.
7. Persistent symptoms, calcium fluctuations, disease-related poor quality of life or renal impairment: discuss PTH replacement with the endocrine team.

Worked Clinical Cases

Common Mistakes

Mistake 1

Low calcium alone diagnoses hypoparathyroidism.

Wrong.

Mistake 2

Normal-range PTH excludes hypoparathyroidism.

Wrong.

Mistake 3

Low calcium should have normal PTH.

Wrong.

It should stimulate PTH.

Mistake 4

Phosphate should be low in hypoparathyroidism.

Wrong.

It is commonly high.

Mistake 5

Vitamin D deficiency and HypoPT have the same PTH pattern.

Wrong.

Mistake 6

Pseudohypoparathyroidism has low PTH.

Wrong.

PTH is high.

Mistake 7

Magnesium does not matter.

Wrong.

Mistake 8

Persistent postsurgical disease at 6 months is definitely permanent.

Outdated.

Current ESE guidance defines chronic postsurgical disease after >12 months. (OUP Academic)

Mistake 9

Treatment goal is high-normal calcium.

Wrong for most conventional treatment.

Mistake 10

Serum calcium alone determines treatment safety.

Wrong.

Mistake 11

Urinary calcium does not matter.

Wrong.

Mistake 12

Ordinary vitamin D replaces calcitriol physiology completely.

Wrong.

Mistake 13

Active vitamin D is unnecessary if 25-OH D is normal.

Wrong.

Mistake 14

Hyperphosphatemia is harmless.

Wrong.

Mistake 15

Thiazides always worsen hypoparathyroidism.

Wrong.

They may help reduce hypercalciuria.

Mistake 16

PTH replacement is experimental only.

Outdated.

Mistake 17

PTH replacement is mandatory for every patient.

Wrong.

Mistake 18

PTH replacement means calcium monitoring is unnecessary.

Wrong.

Mistake 19

High BMD means bone physiology is completely normal.

Wrong.

Mistake 20

Acute symptomatic hypocalcemia can be managed with oral calcium only.

Wrong.

Hypoparathyroidism in One Minute

One-minute revision

HYPOPARATHYROIDISM IN ONE MINUTE

PTH high

Think:

secondary HPT / PTH resistance

PTH low or inappropriate normal

Check:

Chronic treatment:

Target:

Monitor:

Poor control?

Golden rules

Low calcium should increase PTH.

Therefore low calcium with normal-range PTH can still represent hypoparathyroidism.

Hypoparathyroidism classically causes low calcium and high phosphate.

PTH deficiency reduces renal calcium conservation.

PTH deficiency reduces phosphate excretion.

PTH deficiency reduces calcitriol production.

Magnesium deficiency can produce functional hypoparathyroidism.

Pseudohypoparathyroidism has high PTH, not low PTH.

Postsurgical hypoparathyroidism is the most common acquired adult cause.

Current ESE guidance defines chronic postsurgical disease as persisting >12 months.

The treatment goal is symptom control with calcium usually in the lower reference range or slightly below—not normalization at any cost.

Active vitamin D is central to conventional therapy.

Urinary calcium must be monitored.

Hyperphosphatemia matters.

Kidney complications are a major long-term concern.

PTH replacement is an important modern option when conventional treatment is inadequate.

Frequently Asked Questions

Key Take-Home Messages

Hypoparathyroidism becomes easier to recognize when PTH is interpreted against serum calcium.

Normally:

should produce:

Therefore:

or:

is physiologically abnormal.

The next clue is:

Because PTH normally promotes phosphate excretion:

At the same time:

and:

therefore:

The diagnostic sequence is:

The most common adult cause is:

but severe magnesium deficiency, autoimmune disease and genetic disorders must also be considered.

Treatment should not aim to force serum calcium to the upper normal range.

Instead:

while targeting:

and preventing:

Conventional therapy uses:

But when patients remain inadequately controlled despite optimized conventional therapy:

can restore more physiological calcium and phosphate handling.

The final memory rule is:

Hypoparathyroidism is not simply a disease of low calcium. It is a loss of PTH physiology. The diagnosis depends on recognizing that PTH is inappropriately low during hypocalcemia, while successful long-term management requires more than correcting serum calcium—it requires balancing symptoms, phosphate, urinary calcium, renal health and, in selected patients, restoration of PTH itself.